The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)
Open accessAbstract
Purpose Radiation Therapy Oncology Group (RTOG) 9508 showed a survival advantage for patients with 1 but not 2 or 3 brain metastasis (BM) treated with whole-brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) versus WBRT alone. An improved prognostic index, the graded prognostic assessment (GPA) has been developed. Our hypothesis was that if the data from RTOG 9508 were poststratified by the GPA, the conclusions may vary. Methods and Materials In this analysis, 252 of the 331 patients were evaluable by GPA. Of those, 211 had lung cancer. Breast cancer patients were excluded because the components of the breast GPA are not in the RTOG database. Multiple Cox regression was used to compare survival between treatment groups, adjusting for GPA. Treatment comparisons within subgroups were performed with the log-rank test. A free online tool (brainmetgpa.com) simplified GPA use. Results The fundamental conclusions of the primary analysis were confirmed in that there was no survival benefit overall for patients with 1 to 3 metastases; however, there was a benefit for the subset of patients with GPA 3.5 to 4.0 (median survival time [MST] for WBRT + SRS vs WBRT alone was 21.0 versus 10.3 months, P = .05) regardless of the number of metastases. Among patients with GPA 3.5 to 4.0 treated with WBRT and SRS, the MST for patients with 1 versus 2 to 3 metastases was 21 and 14.1 months, respectively. Conclusions This secondary analysis of predominantly lung cancer patients, consistent with the original analysis, shows no survival advantage for the group overall when treated with WBRT and SRS; however, in patients with high GPA (3.5-4), there is a survival advantage regardless of whether they have 1, 2, or 3 BM. This benefit did not extend to patients with lower GPA. Prospective validation of this survival benefit for patients with multiple BM and high GPA when treated with WBRT and SRS is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425 · cited 1×
“An improved and diagnosis-specific prognostic index, the graded prognostic assessment (GPA) has been developed (12-15) and independently validated (16-25).”
MethodSelf-citation
Cited by
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,034
Sperduto, P. W., Yang, T. J., Beal, K., Pan, H., Brown, P. D., Bangdiwala, A., Shanley, R., Yeh, N., Gaspar, L. E., Braunstein, S., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3834 · Cited by 659
Self-citationSoffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., Radbruch, A., Villa Freixa, S. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now241 · Cited by 496
Sperduto, P. W., Mesko, S., Li, J., Cagney, D., Aizer, A., Lin, N. U., Nesbit, E., Kruser, T. J., Chan, J., Braunstein, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01255 · Cited by 471
Self-citationWhole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
Tsao, M. N., Lloyd, N., Wong, R. K., Chow, E., Rakovitch, E., Laperriere, N., Xu, W., & Sahgal, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003869.pub3 · Cited by 399
Metadata
- Authors
- Sperduto, P. W., Shanley, R., Luo, X., Andrews, D., Werner-Wasik, M., Valicenti, R., Bahary, J.-P., Souhami, L., Won, M., & Mehta, M.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 90
- Issue
- 3
- Pages
- 526-531
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2154704485
- Cited by
- 173
- References
- 1
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA). https://app.cochat.ai/papers/10.1016/j.ijrobp.2014.07.002
- The paper
- Sperduto, P. W., Shanley, R., Luo, X., Andrews, D., Werner-Wasik, M., Valicenti, R., Bahary, J.-P., Souhami, L., Won, M., & Mehta, M. (2014). Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA). International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2014.07.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.